TY - JOUR
T1 - Deep learning for advancing peptide drug development
T2 - Tools and methods in structure prediction and design
AU - Wu, Xinyi
AU - Lin, Huitian
AU - Bai, Renren
AU - Duan, Hongliang
N1 - Publisher Copyright:
© 2024 Elsevier Masson SAS
PY - 2024/3/15
Y1 - 2024/3/15
N2 - Peptides can bind challenging disease targets with high affinity and specificity, offering enormous opportunities for addressing unmet medical needs. However, peptides’ unique features, including smaller size, increased structural flexibility, and limited data availability, pose additional challenges to the design process compared to proteins. This review explores the dynamic field of peptide therapeutics, leveraging deep learning to enhance structure prediction and design. Our exploration encompasses various facets of peptide research, ranging from dataset curation handling to model development. As deep learning technologies become more refined, we channel our efforts into peptide structure prediction and design, aligning with the fundamental principles of structure-activity relationships in drug development. To guide researchers in harnessing the potential of deep learning to advance peptide drug development, our insights comprehensively explore current challenges and future directions of peptide therapeutics.
AB - Peptides can bind challenging disease targets with high affinity and specificity, offering enormous opportunities for addressing unmet medical needs. However, peptides’ unique features, including smaller size, increased structural flexibility, and limited data availability, pose additional challenges to the design process compared to proteins. This review explores the dynamic field of peptide therapeutics, leveraging deep learning to enhance structure prediction and design. Our exploration encompasses various facets of peptide research, ranging from dataset curation handling to model development. As deep learning technologies become more refined, we channel our efforts into peptide structure prediction and design, aligning with the fundamental principles of structure-activity relationships in drug development. To guide researchers in harnessing the potential of deep learning to advance peptide drug development, our insights comprehensively explore current challenges and future directions of peptide therapeutics.
KW - Artificial intelligence (AI)
KW - Deep learning (DL)
KW - Peptide design
KW - Peptide structure prediction
KW - Peptide-protein interaction (PepPI)
KW - Structure-based drug design (SBDD)
UR - http://www.scopus.com/inward/record.url?scp=85186442141&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2024.116262
DO - 10.1016/j.ejmech.2024.116262
M3 - Review article
C2 - 38387334
AN - SCOPUS:85186442141
SN - 0223-5234
VL - 268
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
M1 - 116262
ER -